Reglagene Holding, Inc.

Novel therapeutics are lacking for Brain Cancer. Only four of the 217 FDA-approved oncology medicines are indicated for life-threatening brain cancers. The most recent approval was in 2009 and did not extend life expectancy. Patients deserve better therapies that improve quality of life and extend life. The Reglagene team is developing a first-in-class blood–brain barrier (BBB) penetrant medicine that effectively fights brain cancer. Medicines for a global market.